Literature DB >> 22434316

Tumor associated glycoprotein-72 is a novel marker for poor survival in hepatocellular carcinoma.

Yang Zhang1, Zhan-sheng Deng, Ming-mei Liao, Ning Wang, Xiao-qing Zhang, Hai-yang Yu, Yang-de Zhang.   

Abstract

To investigate the relationship of tumor associated glycoprotein-72 (TAG-72) expression with clinicopathological features in hepatocellular carcinoma (HCC) patients. Sixty pairs of HCC and paracarcinomatous (PCLT) tissues, and 10 normal liver (NL) tissues were collected for Western blot analysis, and 244 pairs of HCC and PCLT tissues were collected for immunohistochemistry analysis. TAG-72 protein expression was elevated significantly in HCC tissues compared with PCLT and NL tissues. Its increased expression was correlated with TNM stage, Edmondson-Steiner grade, vein invasion and multiple tumor nodes. It is noteworthy that the HCC patients with high TAG-72 expression had shorter overall survival and disease-free survival than the patients with low expression. Multivariate Cox regression analysis revealed that TAG-72 expression was an independent prognostic factor for HCC patients. The current study demonstrated for the first time that the increased expression of TAG-72 was correlated with poor survival in patients with HCC, indicating that TAG-72 is a novel prognostic marker for HCC.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22434316     DOI: 10.1007/s12253-012-9521-0

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  16 in total

1.  Expression of TAG-72 in ovarian cancer and its correlation with tumor stage and patient prognosis.

Authors:  Moorthy P Ponnusamy; Ganesh Venkatraman; Ajay P Singh; Subhash C Chauhan; Sonny L Johansson; Maneesh Jain; Lynnette Smith; John S Davis; Steven W Remmenga; Surinder K Batra
Journal:  Cancer Lett       Date:  2007-01-08       Impact factor: 8.679

2.  Improved efficacy of alpha-particle-targeted radiation therapy: dual targeting of human epidermal growth factor receptor-2 and tumor-associated glycoprotein 72.

Authors:  Diane E Milenic; Erik D Brady; Kayhan Garmestani; Paul S Albert; Alia Abdulla; Martin W Brechbiel
Journal:  Cancer       Date:  2010-02-15       Impact factor: 6.860

3.  Detection of serum gastric cancer-associated MG7-Ag from gastric cancer patients using a sensitive and convenient ELISA method.

Authors:  Bin Jin; Xin Wang; Yan Jin; Wensen Xia; Bei Chen; Lin Liu; Zheng Chen; Liu Hong; Wenqi Du; Kun Yan; Honghong Wang; Donghong Yuan; Xiaoli Hui; Li He; Faming Zhang; Yunping Zhao; Kaichun Wu; Daiming Fan
Journal:  Cancer Invest       Date:  2009-02       Impact factor: 2.176

Review 4.  Immunoreactivity and prognostic value of tumor-associated glycoprotein 72 in primary gallbladder carcinoma.

Authors:  Miao Ouyang; Wei Wu; Yiyou Zou; Jun Zhou; Zhiming Wang; Xiaoping Wan
Journal:  Surg Oncol       Date:  2009-05-15       Impact factor: 3.279

5.  Near-infrared fluorescence labeled anti-TAG-72 monoclonal antibodies for tumor imaging in colorectal cancer xenograft mice.

Authors:  Peng Zou; Songbo Xu; Stephen P Povoski; Anna Wang; Morgan A Johnson; Edward W Martin; Vish Subramaniam; Ronald Xu; Duxin Sun
Journal:  Mol Pharm       Date:  2009 Mar-Apr       Impact factor: 4.939

6.  Combination therapy with Pretarget CC49 radioimmunotherapy and gemcitabine prolongs tumor doubling time in a murine xenograft model of colon cancer more effectively than either monotherapy.

Authors:  Scott S Graves; Erica Dearstyne; Yukang Lin; Yuting Zuo; James Sanderson; Jody Schultz; Anastasia Pantalias; David Gray; Don Axworthy; H Mark Jones; Karen Auditore-Hargreaves
Journal:  Clin Cancer Res       Date:  2003-09-01       Impact factor: 12.531

7.  Apocrine carcinoma, adenopathies, and raised TAG-72 serum tumor marker.

Authors:  Jorge Santos-Juanes; José Francisco Bernaldo de Quirós; Cristina Galache Osuna; José Sánchez del Río; María Teresa Allende; María Victoria Folgueras; Jorge Soto de Delás
Journal:  Dermatol Surg       Date:  2004-04       Impact factor: 3.398

Review 8.  The use of monoclonal antibodies for the treatment of epithelial ovarian cancer (review).

Authors:  Angèle L M Oei; Fred C G J Sweep; Chris M G Thomas; Otto C Boerman; Leon F A G Massuger
Journal:  Int J Oncol       Date:  2008-06       Impact factor: 5.650

9.  Mucins CA 125, CA 19.9, CA 15.3 and TAG-72.3 as tumor markers in patients with lung cancer: comparison with CYFRA 21-1, CEA, SCC and NSE.

Authors:  Rafael Molina; Jose Maria Auge; Jose Miguel Escudero; Ramon Marrades; Nuria Viñolas; Emilio Carcereny; Jose Ramirez; Xavier Filella
Journal:  Tumour Biol       Date:  2008-12-08

10.  A new TAG-72 cancer marker peptide identified by phage display.

Authors:  Ling Chen; Yi Wang; Xinrong Liu; Shuping Dou; Guozheng Liu; Donald J Hnatowich; Mary Rusckowski
Journal:  Cancer Lett       Date:  2008-08-23       Impact factor: 8.679

View more
  4 in total

1.  A Fas Ligand (FasL)-Fused Humanized Antibody Against Tumor-Associated Glycoprotein 72 Selectively Exhibits the Cytotoxic Effect Against Oral Cancer Cells with a Low FasL/Fas Ratio.

Authors:  Ming-Hsien Chien; Wei-Min Chang; Wei-Jiunn Lee; Yu-Chan Chang; Tsung-Ching Lai; Derek V Chan; Rahul Sharma; Yuan-Feng Lin; Michael Hsiao
Journal:  Mol Cancer Ther       Date:  2017-03-14       Impact factor: 6.261

Review 2.  Tissue- and Serum-Associated Biomarkers of Hepatocellular Carcinoma.

Authors:  Ranjit Chauhan; Nivedita Lahiri
Journal:  Biomark Cancer       Date:  2016-07-04

Review 3.  Tumor markers for hepatocellular carcinoma.

Authors:  Yan-Jie Zhao; Qiang Ju; Guan-Cheng Li
Journal:  Mol Clin Oncol       Date:  2013-05-13

4.  Aptamer-Functionalized Drug Nanocarrier Improves Hepatocellular Carcinoma toward Normal by Targeting Neoplastic Hepatocytes.

Authors:  Samrat Chakraborty; Zewdu Yilma Dlie; Somdyuti Chakraborty; Somdatta Roy; Biswajit Mukherjee; Shila Elizabeth Besra; Saikat Dewanjee; Alankar Mukherjee; Probir Kumar Ojha; Vinay Kumar; Ramkrishna Sen
Journal:  Mol Ther Nucleic Acids       Date:  2020-02-05       Impact factor: 8.886

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.